Skip to content
Screener

Castle Biosciences CSTL Business Segments — D&A

Similar metrics at other companies

OLP
OLPXReportable Segment — D&A
$13.32M-0.4%
V2X logo
VVXReportable Segment — D&A
$28.11M+0.3%
DocuSign logo
DOCUReportable Segment — D&A
$32.21M+6.1%
Chewy logo
CHWYReportable Segment — D&A
$37M+23.3%
CWA
CWANReportable Segment — D&A
$29.56M+840%
Intuitive Machines, Inc. logo
LUNRReportable Segment — D&A
$13.05M+1,994%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$978.5M+76.1%
Enterprise value$951.46M+86.2%
P/S2.9×+1.3×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-031263
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
OPERATING ACTIVITIES
Net loss$(14,522)$(25,848)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization3,92929,764
Stock-based compensation expense9,77611,179
Net (gains) losses on equity securities(2,022)1,425
Deferred income taxes(10)(770)
Accretion of discounts on marketable investment securities(454)(1,435)

Item 1. Financial Statements.

FAQ

What is Castle Biosciences's business segments — D&A?
Castle Biosciences (CSTL) reported business segments — D&A of $3.93M in Q1 2026.
How has Castle Biosciences's business segments — D&A changed year-over-year?
Castle Biosciences's business segments — D&A decreased by 86.8% year-over-year, from $29.76M to $3.93M.
What is the long-term trend for Castle Biosciences's business segments — D&A?
Over 3 years (2022 to 2025), Castle Biosciences's business segments — D&A has grown at a 57.0% compound annual growth rate (CAGR), from $10.54M to $40.77M.
What does business segments — D&A mean?
This represents the non-cash expense allocated to the reportable segment for the systematic reduction in the value of tangible and intangible assets over their useful lives. It reflects the capital intensity of the segment's operations and the ongoing investment required to maintain its diagnostic infrastructure.

Ask your AI about Castle Biosciences's business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude